In a patent case that could change the way drug companies enter into licensing agreements, the U.S. Supreme Court has ruled that biotech firm MedImmune Inc. may sue its licensing partner Genentech Inc. over one of the most famous patents in biotech.
The court’s 8-1 decision Tuesday — only Justice Clarence Thomas dissented — reversed several lower court rulings that said MedImmune couldn’t pay license fees on a patent and sue to have the patent overturned at the same time.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
